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Abstract
Background: Myofibrillogenesis regulator 1 (MR-1) is overexpressed in human cancer cells and plays an essential
role in cancer cell growth. However, the significance of MR-1 in human ovarian cancer has not yet been explored.
The aim of this study was to examine whether MR-1 is a predictor of ovarian cancer and its value as a therapeutic
target in ovarian cancer patients.
Methods: Reverse-transcription polymerase chain reaction (PCR) and quantitative real-time PCR were used to
detect MR-1 mRNA levels in tissue samples from 26 ovarian cancer patients and 25 controls with benign ovarian
disease. Anti-MR-1 polyclonal antibodies were prepared, tested by ELISA and western blotting, and then used for
immunohistochemical analysis of the tissue samples. Adhesion and invasion of 292T cells was also examined after
transfection of a pMX-MR-1 plasmid. Knockdown of MR-1 expression was achieved after stable transfection of
SKOV3 cells with a short hairpin DNA pGPU6/GFP/Neo plasmid against the MR-1 gene. In addition, SKOV3 cells
were treated with paclitaxel and carboplatin, and a potential role for MR-1 as a therapeutic target was evaluated.
Results: MR-1 was overexpressed in ovarian cancer tissues and SKOV3 cells. 293T cells overexpressed MR-1, and
cellular spread and invasion were enhanced after transfection of the pMX-MR-1 plasmid, suggesting that MR-1 is
critical for ovarian cancer cell growth. Knockdown of MR-1 expression inhibited cell adhesion and invasion, and
treatment with anti-cancer drugs decreased its expression in cancer cells. Taken together, these results provide the
first evidence of the cellular and molecular mechanisms by which MR-1 might serve as a novel biological marker
and potential therapeutic target for ovarian cancer.
Conclusions: MR-1 may be a biomarker for diagnosis of ovarian cancer. It may also be useful for monitoring of the
effects of anti-cancer therapies. Further studies are needed to clarify whether MR-1 is an early diagnostic marker for
ovarian cancer and a possible therapeutic target.
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Background
Ovarian cancer is the leading cause of cancer-related
death in women worldwide. The American Cancer
Society revealed that 21,550 women in the US were
diagnosed with ovarian cancer and 14,600 women died
of the disease in 2009 [1]. In China, the number of
patients with ovarian cancer has increased in recent
years, and the 5-year survival rate is less than 30%.
Metastasis is the major cause of disease progression and
therapeutic failure [2].
Myosin light chain-2 (MLC2) plays an important role
in cell migration from solid tumors such as ovarian can-
cer, and its dephosphorylation can induce apoptosis
[3,4]. A recent report indicated that MLC2 may regulate
cell proliferation and migration by interacting with myo-
fibrillogenesis regulator 1 (MR-1) [5]. Overexpression of
MR-1 is associated with cancer cell proliferation and
migration in human hepatoma HepG2 cells [6]. MR-1,
mapped to 2q35 and first cloned from a human skeletal
muscle cDNA library using PCR and rapid amplification
* Correspondence: guolin500@hotmail.com
1Department of Clinical Laboratory, Shanghai Cancer Center, Fudan
University, Shanghai, China
Full list of author information is available at the end of the article
Lu et al. BMC Cancer 2011, 11:270
http://www.biomedcentral.com/1471-2407/11/270
© 2011 Lu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
of cDNA ends (Genbank™ accession no. AF417001), is
a protein of 142 amino acids [7-10]. MR-1 may promote
cancer cell proliferation by binding to specific proteins,
such as eukaryon initiation factor 3, which is highly
associated with the regulation of tumor cell growth and
invasion [11]. Also, overexpression of MR-1 can activate
the nuclear factor B signaling pathway, which is linked
to a wide variety of diseases including cancer, inflamma-
tion and autoimmune disease [12].
Taking all the evidence into account, we hypothesized
that MR-1 may play a role in the development and pro-
gression of ovarian cancer, probably by promoting cell
proliferation and invasion. The present study examined
MR-1 expression in ovarian cancer tissues and a cancer
cell line. Overexpression or knockdown of MR-1 in can-
cer cells was used to assess its role in cell proliferation,
adhesion, and invasion. Finally, the response of MR-1 to
treatment with anti-cancer drugs was assessed to iden-
tify whether it functions as a novel biological marker
and therapeutic target for ovarian cancer.
Methods
Human Tissue Samples and Cell Lines
All human samples were collected in compliance with
the guidelines of the Ethics Committee at the Fudan
University Cancer Hospital. Fresh-frozen surgical ovar-
ian tissue samples were collected from 26 patients with
ovarian cancer (aged 20-58 years) and 20 control
patients with benign ovarian disease (aged 23-55 years)
who were admitted to Fudan University Cancer Hospital
(Shanghai, China) between July 2008 and December
2009. All cases were confirmed by pathology. The sam-
ples were defatted, immediately cut into pieces of appro-
priate size on ice, and stored at -80°C for later use. The
ovarian carcinoma cell line, SKOV3, and the non-ovar-
ian cancer cell line, 293T, were generous gifts from Dr.
Meiqin Zhang, Laboratory of Gynecologic Oncology,
Fudan University Shanghai Cancer Center, Shanghai.
Reverse-Transcription Polymerase Chain Reaction (RT-
PCR) and Quantitative Real-Time PCR
Total RNA was extracted from the cells using the TRIzol
reagent (Invitrogen, NY, USA) according to the manufac-
turer’s protocol, and the RNA concentration was deter-
mined using a Nanodrop spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). RT-PCR was carried
out using a SuperScript™ one-step RT-PCR kit (Invitro-
gen) according to the manufacturer’s instructions. cDNA
was synthesized from 2 μg of total RNA at 42°C for 45
min, followed by inactivation of the reverse transcriptase
at 85°C for 5 min. The cDNA was then subjected to PCR
to amplify the MR-1 and GAPDH (control) genes in 50
μL reaction mixture containing the following primers:
MR-1 forward 5’-CCCAGAAAGAGGG GCAAGA-3’
(P1), MR-1 reverse 5’-TGAGGATGAAGAG GAGGA-
TACCA-3’ (P2), GAPDH forward 5’-GGGAGC-
CAAAAGGGTCATCATCTC-3’ (P1) GAPDH reverse 5’-
CCATGCCAGTGAGCTTC CCGTTC-3’ (P2). The
cycling conditions were: initial denaturation at 95°C for 3
min, followed by 36 cycles of denaturation at 94°C for 30
s, annealing at 55°C for 30 s, and extension at 72°C for 45
s. PCR products were resolved and analyzed on a 2%
TAE agarose gel containing ethidium bromide. Quantita-
tive real-time PCR for MR-1 (GAPDH as internal con-
trol) was performed in an MJ PCR system (Reno, NV,
USA) using a 20 μL reaction volume containing 10 μL of
SYBR® Premix Ex Taq™ reagent (Takara, Dalian, China),
0.5 pmol of each primer, 1 μg of cDNA, and the same
sets of primers and cDNAs. The conditions were: an
initial denaturation step at 94°C for 10 min, followed by
40 cycles of 15 s at 95°C (denaturation), 30 s at 55°C
(annealing), and 30 s at 72°C (extension). Delta Ct (CtMR-
1-CtGAPDH) was calculated for each set of samples and
compared.
Vector Construction and Production of MR-1
Recombinant Protein
Human MR-1 cDNA was synthesized by reverse tran-
scription from the mRNA (sequence originally published
by Li et al [7]). A 429-bp fragment was amplified from
the synthesized cDNA by PCR using Taq PCRx® DNA
polymerase (Invitrogen) to introduce BamHI and XhoI
restriction sites using the primers 5’-CGGGATC-
CATGGCGGCGGTGGTAGCTGC-3’ (P3, BamHI site
underlined) and 5’-CCGCTCGAGTCAGGTCTG-
CACCCCAGAC-3’ (P4, XhoI site underlined). The
cDNA fragment was then cloned into the PET21a (+)
expression vector (Invitrogen) to yield PET21a-MR1,
which was then transformed into Escherichia coli BL21
(DE3) cells for expression of the MR-1 recombinant pro-
tein [13]. The MR-1 recombinant protein contained a
T7-tag at the N-terminus and 6 × His-tag at the C-termi-
nus and was purified using Ni-resin affinity chromatogra-
phy. The purified protein was confirmed by western
blotting with a mouse anti-His PcAb (Invitrogen).
Antibody Production
New Zealand white rabbits were immunized four times
with the MR-1 recombinant protein. Sera were har-
vested 3 days after the final immunization if the rabbits
showed a good anti-MR-1-His titer. The anti-MR-1 anti-
bodies R1 and R2 were then affinity-purified using a
protein A column (Pierce Biotechnology Inc., Rockford,
IL, USA). The antibody titers were measured using an
enzyme-linked immunosorbent assay (ELISA), and
immunoreactivity was confirmed by western blotting
with MR-1 recombinant protein and human ovarian
cancer cells (SKOV3).
Lu et al. BMC Cancer 2011, 11:270
http://www.biomedcentral.com/1471-2407/11/270
Page 2 of 10
Immunocytochemistry
Immunohistochemical staining was performed on 6-μm
sections from formalin-fixed, paraffin-embedded human
tissues. The slides were deparaffinized and rehydrated in
graded ethanol solutions. Antigen retrieval was per-
formed by heating the samples in a microwave oven for
20 min in citrate buffer (pH 6.0). The slides were then
incubated with the affinity-purified MR-1 antibody
(1:200) followed by incubation with a horseradish perox-
idase-labeled polymer conjugated to a goat anti-rabbit
immunoglobulin antibody (1:4000; R&D Systems, Min-
neapolis, MN, USA). Color was developed using diami-
nobenzidine as a chromogen and the slides were
counterstained with hematoxylin. An anti-His antibody
and polyclonal non-immune rabbit IgG were used as
negative controls to check the specificity of the MR-1
affinity-purified antibody. Immunocytochemical staining
of SKOV3 cells was performed on cover slips by fixing
the cells for 20 minutes in acetone, blocking with 2%
bovine serum albumin, and then incubating with affi-
nity-purified anti-MR1 antibody followed by DAB stain-
ing and hematoxylin counterstaining. Dark brown
cytoplasmic staining was defined as positive and no (or
faint) staining was defined as negative. The proportion
of tumor cells positive for MR-1 varied considerably:
diffuse positive (> 50%), focal or heterogeneous (10%-
50%), and trace (< 10%).
Establishment of Stable Cell Line Overexpressing MR-1
The full-length coding sequence for the MR-1 cDNA
was subcloned into the pMX-puro(+) vector (Invitrogen)
to yield pMX-MR-1, which was then transfected into
293T cells using Fusion 6® (Roche, Mannheim, Ger-
many) according to the manufacturer’s instructions. A
pMX-mock vector (pMX-puro(+) containing a random
non-MR-1 DNA sequence) was used as the control. Pur-
omycin (0.5 μg/ml; Invitrogen) was added to the cells 48
h after transfection to select stably transfected clones.
Single clones were picked from both pMX-MR-1 and
pMX-mock transfected samples, and RNA and protein
were extracted to check the expression levels of MR-1
by real-time PCR and western blotting. Positive clones
were designated pMX-MR-1-293T, and control clones
as pMX-mock-293T. 293T cells were cultured in Dul-
becco modified Eagle medium (DMEM) supplemented
with high glucose, 10% fetal bovine serum (FBS, Gibco
BRL, Grand Island, NY, USA), and 1% penicillin/strepto-
mycin at 37°C in 5% CO2.
Cell Proliferation and Invasion Assays
For the cell proliferation assay, pMX-MR-1-293T and
pMX-mock-293T cells were grown at a density of 1000
cells/ml in 24-well plates with regular medium changes.
The cell number was counted every 24 hours for 6 days
as follows: cells were detached by brief exposure to
0.025% trypsin containing 2 mM EDTA in PBS, washed
in culture medium without FBS, and then resuspended
in the same medium for manual cell counting. For the
invasion assays, Matrigel was thawed at 4°C overnight,
diluted in cold serum-free culture medium, plated onto
24-well plates preloaded with Transwell™ culture
inserts (12 mm diameter, 8 μm pore size; Costar, Cam-
bridge, MA, USA) and incubated for 5 hours at 37°C for
gelling. The cells were then plated onto the Transwell™
inserts (50,000 cells/well) and cultured at 37°C in 5%
CO2. After 16 hours, the cells on the upper side of the
well were removed and fixed prior to staining with
hematoxylin and eosin. Cells migrating to the underside
were counted under a microscope. All experiments were
repeated at least three times.
MR-1 Knockdown Using RNAi
SKOV3 cells were cultured in Gibco® RPMI 1640 (Invi-
trogen) supplemented with 10% heat-inactivated FBS
and 1% penicillin/streptomycin at 37°C in a humidified
atmosphere containing 5% CO2. When the cells reached
70-80% confluence, they were transfected with pGPU6-
MR-1 short hairpin DNA (shDNA) targeting MR-1. The
sequences of the shDNAs were as follows: shDNA 232:
5’-CACCGCTAACAAGGCTTCTCATAACTTCAAGA-
GAGT TATGAGAAGCCTTGTTAGCTTTTTG-3’;
shDNA 442: 5’-CACCGACCGTGTGA AGCAGAT-
GAAGTTCAAGAGACTTCATCTGCTTCACACGG
TCTTTTTTG-3’; shDNA 584: 5’-CACCGACCCTCCTA
GGCTATTGACTTTCAAGAGAAGTCAATA GCCTA
GGAGGGTCTTTTTTG-3’; mock sequence: 5’-CA
CCGTTCTCCGAACGT GTCACGTCAAGAGATTA
CGTGAGACGTTCGGAGAATTTTTTG-3’. The pGP
U6-shDNA plasmids were constructed by cloning the
respective shDNAs into the pGPU6/GFP/Neo vector
(Invitrogen). The cells were exposed to 1500 μg/ml
G418 (Invitrogen) for 2 days after transfection to select
for stably transfected clones. Cells were then plated at a
lower density in 96-well plates containing RPMI 1640
and G418 (750 μg/ml) until single colonies were formed.
Colonies from the SKOV3-MR-1-shDNA and SKOV3-
mock-shDNA-transfecetd cells were then picked and
expanded. Real-time PCR and western blotting were
used to test the expression levels of MR-1. GAPDH was
used as the internal control.
Effects of Anti-Tumor Drugs on MR-1 Expression
SKOV3 cells (50,000 cells/well) were cultured in six-well
plates in RPMI 1640 under the conditions described
above. After 24 hours, 10 μL of serially diluted paclitaxel
(equivalent to 0, 12.5, 25, 50, 100 nmol/L; Bristol-Myers
Squibb Inc., USA) or carboplatin (equivalent to 0, 40,
80, 160, 320 mg/L) (Qilu Pharmacy Inc., China) were
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added to the medium and the cells were cultured for an
additional 48 hours. One set of cells was treated with
TUNEL reagent (Roche) and counterstained with DAPI,
and the number of apoptotic cells (stained by Annexin
V-FITC/PI) was determined by flow cytometry (Becton
Dickinson, USA). The other set of cells was harvested
for RNA and protein extraction, and the expression
levels of MR-1 were determined by real-time RT-PCR
and western blotting.
Statistical analysis
Statistical analysis was performed using Analysis of Var-
iance (ANOVA) and the post-hoc Student-Newman-
Keuls test, with SPSS software version 13.0 (SPSS Inc.,
Chicago, IL, USA). The results were expressed as the
mean ± SD. A P value < 0.05 was considered significant.
Results
MR-1 Is Differentially Expressed in Human Malignant and
Benign Ovarian Tumors
Tissue MR-1 mRNA levels were analyzed by RT-PCR and
quantitative real-time PCR to investigate the expression of
MR-1 in malignant and benign ovarian tumors. RT-PCR
showed that the mRNA expression level was higher in
ovarian cancer patients than in controls (Figure 1A). Quan-
titative real-time PCR also showed that MR-1 expression
was significantly higher in tumor tissues from ovarian can-
cer patients (n = 26) than in control patients (n = 25) (P <
0.05; Figure 1B). Western blotting showed a higher level of
MR-1 protein expression in ovarian cancer tissues.
Production of MR-1 PcAbs
Immunization of rabbits with MR-1 recombinant proteins
(Figure 2A) successfully yielded anti-MR-1 antibodies,
which were then affinity-purified (Figure 2B). The PcAbs,
named R1 and R2, were further assessed by ELISA and
western blotting. The results showed that both antibodies,
particularly R2, reacted with the MR-1 protein, and had a
titer of around 1:5 × 105 (Figure 2C and 2D).
Overexpression of MR-1 in Ovarian Cancer
Immunohistochemical staining of 26 ovarian cancer tis-
sue samples and 20 ovarian cyst samples showed that the
MR-1 protein was located in both the cytoplasm and
nuclei of ovarian carcinoma cells, whereas the epithelial
cells of the cysts were negative (Figure 3A and 3B). Dif-
fuse staining for MR-1 was observed in ovarian cancer
cells, particularly serous papillary ovarian cancer cells,
compared with the benign control group. Approximately
73% (19/26) of ovarian carcinoma samples showed dif-
fuse positive staining, 19% (5/26) showed focal or hetero-
geneous staining, and 8% (2/26) showed trace staining.
The control anti-His antibody and the purified non-
immune rabbit IgG showed negative staining (data not
shown). High MR-1 expression and a similar staining
pattern were detected in SKOV3 cells (Figure 3C).
MR-1 Overexpression Promotes Cell Adhesion and
Invasion
This is the first report describing the generation of
pMX-mock- and pMX-MR-1-stably-transfected 293T
cells. Tests were conducted to ensure that overexpres-
sion of MR-1 did not affect proliferation of the 293T
cells; however, the density of 293T-pMX-MR-1 cells was
higher (Figure 4A). RT-PCR and real-time PCR revealed
that pMX-MR-1-stably-transfected 293T cells had much
higher levels of MR-1 mRNA expression than control
pMX-mock-stably-transfected 293T cells (Figure 4B and
     




Figure 1 MR-1 mRNA levels detected by RT-PCR and real-time quantitative PCR. (A) RT-PCR products from cells and tissue samples from
patients with ovarian cancer were visualized on 2% agarose gels. Upper panel: MR-1 RT-PCR products from SKOV3 cells (Lane 1), two samples
from patients with benign ovarian disease (Lanes 2, 3), and three samples from patients with ovarian cancer (Lanes 4, 5, 6). Lower panel: GAPDH
RT-PCR controls for the above samples in the same order (Lanes 7-12). (B) Real-time quantitative PCR of ovarian cancer patients (n = 26) showed
increased MR-1 mRNA levels compared with controls. **P < 0.05.
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4C). This was mirrored by protein expression levels as
assessed by western blotting (Figure 4D). pMX-MR-1-
stably-transfected 293T cells appeared to aggregate to a
greater extent than pMX-mock-stably-transfected 293T
cells, indicating enhanced cell adhesion, which is a key
step in the cell invasion process. As cells adhere and
spread, they generate traction and thereby migrate
through the substrate. The results of the Transwell
assays showed that transfection with pMX-MR-1 signifi-
cantly promoted the invasion of 293T cells (Figure 4E).
Effects of MR-1 Knockdown on Cell Proliferation,
Adhesion and Spreading
SKOV3 cells constitutively overexpress MR-1. To
further investigate the function of MR-1, we constructed
MR-1-shDNA recombinant plasmids and stably
transfected them into SKOV3 cells to knockdown the
expression of MR-1. RT-PCR, real-time PCR and wes-
tern blotting showed that MR-1 expression was dramati-
cally down-regulated at both the mRNA and protein
levels in SKOV3-MR-1-shDNA-442 and -232 cells (par-
ticularly SKOV3-MR-1-shDNA-442) compared with
SKOV3-shDNA-mock cells (Figure 5A-C). Both the rate
of MR-1-shDNA-transfected SKOV3 cell proliferation
and the degree of adhesion decreased, and the vigor of
the cells was weakened (Figure 5D). Non-transfected
SKOV3 cells and SKOV3-shDNA-mock cells began to
spread 60 min after plating and became flattened by 120
min; however, the spreading of MR-1-shDNA-442 and
parental cells was significantly delayed. These results
indicate that MR-1 plays an important role in ovarian
cancer cell adhesion, spreading and invasion.
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Figure 2 Preparation of MR-1 recombinant protein and anti-MR-1 polyclonal antibodies (PcAbs). (A) Construction of the of MR-1
expression plasmid. (B) The induced and purified MR-1 recombinant protein was visualized by 15% sodium dodecylsulfonate-polyacrylate gel
electrophoresis (SDS-PAGE). Lanes 1-3: expressed products of MR-1 recombinant protein at 0 h, 2 h and 4 h; Lane 1’: unpurified MR-1 protein;
Lane 2’: purified MR-1 protein; M: protein molecular weight ladder (170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa). (C) The titer of anti-MR-1 PcAbs
was tested by ELISA (R1: > 1:40,000; R2: > 1:80,000). (D) Western blotting of the MR-1 protein. Upper panel: MR-1 recombinant protein at 0 μg (a,
d), 0.1 μg (b, e), 1 μg (c, f) was detected by anti-MR-1 PcAbs R1 and R2 at a dilution of 1:2000. Lower panel: Total protein from SKOV3 cell lysates
at 0 μg (a’), 1 μg (b’) and 10 μg (c’) was detected by anti-MR-1 PcAb R2 at a dilution of 1:2000.
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Role of MR-1 in Anti-Cancer Drug Therapy
To identify whether MR-1 is a potential therapeutic tar-
get, SKOV3 cells were treated with different concentra-
tions of the anti-cancer drugs, paclitaxel and
carboplatin. Untreated SKOV3 cells grew as usual, with
a spear-like shape. After treatment with paclitaxel or
carboplatin for 48 hours, the number of cells decreased
slightly and showed morphological changes. As the drug
concentrations increased, the cells gradually shrank and
their nuclei developed apoptosis-like changes, such as
the appearance of green TUNEL-positive cores and the
aberrant accumulation of granules within the nuclei
(Figure 6A). MR-1 expression decreased in a dose-
dependent manner at both the mRNA and protein levels
following treatment with paclitaxel or carboplatin. Flow
cytometry showed that the level of apoptosis also
increased with increasing paclitaxel or carboplatin
concentrations; although the degree of apoptosis
decreased in cells treated with carboplatin at 160 mg/L,
both mRNA and protein levels of MR-1 increased (Fig-
ure 6C).
Discussion
Cancer progression and metastasis is a highly complex
multi-stage process involving alterations in gene expres-
sion, increased cell adhesion, and changes in cell moti-
lity. Cancer cells move within tissues during invasion
and metastasis, and cell invasion involves multiple pro-
cesses that are regulated by various molecules [14].
Ovarian cancer has a high mortality, in large part owing
to fact that the cells migrate and metastasize. This is a
synergistic action associated with multiple factors,
including overexpression of related genes, inhibition of
tumor suppressor genes, and a failure to regulate cell
 î  î  î
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Figure 3 Expression of MR-1 protein in human ovarian tissues and ovarian cancer cell lines (Left to right: magnification = × 40, ×200,
and × 400). (A) Ovarian epithelial cells from cysts were negative for MR-1. (B) Serous papillary ovarian carcinoma cells stained positive for MR-1
in the cytoplasm and nuclei (bold arrow). (C) SKOV-3 cells showed strong cytoplasmic and nuclear staining for MR-1 (dashed arrow).
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Figure 4 MR-1 expression in 293T-pMXs-MR-1 and 293T-pMX cells. (A) Cell proliferation was assessed by cell counting, and cell growth was
observed under an optical microscope. (B, C) 293T-pMX-MR-1 cells showed increased MR-1 levels as detected by RT-PCR and real-time
quantitative PCR. (D) Western blotting showed increased levels of MR-1 protein expression in 293T-pMX-MR-1 cells. (E) Representative images of
migrated cells (left: × 400, arrow). Invasiveness of 293T was enhanced by transfection of the MR-1 gene (right). All experiments were repeated at
least three times. **P < 0.05; ***P < 0.01 compared with pMX-mock control.
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proliferation. Ovarian cancer is a major health care issue
worldwide; therefore, a sensitive biomarker that can
detect ovarian cancer at the curative stage is urgently
needed. Based on the finding that MR-1 plays a role in
promoting the proliferation and invasion in some types
of human cancers [6,12], and following our successful
identification of the association between human epididy-
mis protein 4 and ovarian cancer [15], we designed this
study to comprehensively investigate the association
between MR-1 and ovarian cancer and the roles it may
play in pathogenesis or disease progression.
There are no reports examining the role of MR-1 in
ovarian cancer. This is the first study showing that expres-
sion of MR-1 is increased in ovarian cancer tissues at both
the mRNA and protein levels compared with benign con-
trol tissues. The immunohistochemistry results show that
Figure 5 Inhibition of cell proliferation by down-regulating MR-1. (A) RT-PCR showed that expression of the MR-1 gene decreased in SKOV3
cells transduced with MR-1 ShDNA-442, ShDNA-232, ShDNA-584 (left to right: ShDNA-mock, ShDNA-442, -232, and -584). (B) Expression of the
MR-1 gene was markedly reduced in SKOV3 cells transfected with ShDNA-442, -232, and -584, (particularly with ShDNA-442) as analyzed by two-
way ANOVA. (C) MR-1 protein levels were also decreased in SKOV3 cells transfected with ShDNA-442, and -232 (but not ShDNA-584). ***P < 0.01,
**P < 0.05 compared with shDNA-mock controls. (D) SKOV3 cells transfected with ShDNA-442, and -232 showed inhibited proliferation and
delayed spreading (left). Reduced expression of MR-1 protein fused to GFP in SKOV3 transfected with ShDNA-442 (right).
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MR-1 is abundantly expressed in tumor tissues from ovar-
ian cancer patients, particularly those with serous papillary
ovarian cancer (Figure 3B), and that MR-1 is expressed in
the cytoplasm of ovarian cancer cells (though it is nor-
mally localized to the nuclear membrane). To further
examine the expression of MR-1 in ovarian cancer cells,
RT-PCR and western blotting were used to analyze the
ovarian cancer cell line, SKOV3. SKOV3 is derived from a
human ovarian serous cystadenocarcinoma, which
accounts for over 70% of ovarian cancers. The results
showed that this cell line constitutively expresses high
levels of MR-1 (Figure 1A and 2D).
MR-1-stably-transfected 239T cells were established to
investigate the potential role of MR-1 in cell invasion
$
Figure 6 Relationship between MR-1 expression levels and cell apoptosis. (A) The degree of apoptosis in SKOV3 cells treated by the anti-
tumor drugs, paclitaxel and carboplatin, is shown (apoptotic cells appear as bright green spots, some of which are highlighted with arrows).
Upper panel: a-d show SKOV3 cells treated for 48 h with 0, 12.5, 25, and 50 nmol/L paclitaxel. Lower panel: e-h show SKOV3 cells treated for 48 h
with 0, 40, 80 and 160 mg/L carboplatin. (B, C) The rate of apoptosis was associated with MR-1 gene and protein expression levels.
Representative example from three independent experiments is shown. **P < 0.05; ***P < 0.01 compared with the untreated group (one-way
ANOVA).
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and tumor progression (Figure 4B and 4C). These cells
were used in Matrigel assays to examine cell adhesion
and invasion. MR-1-stably-transfected cells showed
increased aggregation and secreted proteinases that
degrade constituents of the extracellular matrix. They
also migrated faster than mock control cells. This sug-
gests that MR-1 may play a role in cancer progression
by regulating cell adhesion and motility. To confirm
this, MR-1 expression by SKOV3 cells was knocked
down by stable transfection of specific shDNAs. As
expected, SKOV3 cells overexpressing MR-1 shDNA
(known to significantly knock down the expression of
MR-1) showed decreased adhesion, reduced vigor, and
delayed spreading compared with cells transfected with
mock-shDNA (Figure 5D). This further suggests that
MR-1 plays an important role in ovarian cancer cell
adhesion, spreading and invasion.
To assess whether MR-1 is a potential therapeutic target,
SKOV3 cells were treated with the anti-cancer drugs pacli-
taxel and carboplatin, both of which induce apoptosis and
are commonly used to treat ovarian cancer [16]. The num-
ber of apoptotic cells increased and MR-1 mRNA and pro-
tein levels decreased with increasing doses of either
paclitaxel or carboplatin, strongly indicating that these anti-
cancer drugs exert their therapeutic effects by antagonizing
the effects of MR-1. Thus, MR-1 is potentially a novel ther-
apeutic target for the treatment of ovarian cancer.
Conclusion
This study shows that MR-1 is overexpressed in ovarian
cancer tissue and cell lines. Knockdown of MR-1 expres-
sion inhibits cell adhesion and invasion, and anti-cancer
drugs decrease the expression levels of MR-1 in cancer
cells. Thus, MR-1 may be a novel biological marker and
potential therapeutic target for the treatment of ovarian
cancer. It could also be used to monitor the effect of
anti-cancer therapies. Further studies are needed to clar-
ify whether MR-1 is an early diagnostic marker for ovar-
ian cancer and to develop its full therapeutic potential.
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